Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human S100A8 Protein, Tag free, 100µg  

Recombinant human S100A8 Protein, Tag free, 100µg

Recombinant human S100A8 Protein, Met 1-Glu 93, expressed in E.coli cell, Tag free

Synonym
recombinant, human protein, S100A8, 60B8AG, CAGA, CFAG, CGLA, MIF, MRP8, NIF, P8

More details

S18-H5112-100

Availability: within 7 days

264,00 €

Background
S100 calcium binding protein A8 (S100-A8), also kown as Cystic fibrosis antigen, Migration inhibitory factor-related protein 8 60B8AG, CAGA, CFAG, CGLA, CP-10, L1Ag, MA387, MIF, MRP8, NIF and P8, is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. Most S100 proteins are disulfide-linked homodimer, and is normally present in cells derived from the neural crest, chondrocytes, macrophages, dendritic cells, etc. S100A8 plays a role in various functions of myeloid cells by forming a heterocomplex with S100A9. S100A8 and S100A9 are known to be overexpressed in certain species of carcinomas. S100A8 may function in the inhibition of casein kinase and as a cytokine. Altered expression of this protein is associated with the disease cystic fibrosis.[1] S100A8 plays an important role in differentiation of thyroid carcinoma possibly by forming a complex with S100A9. S100A8 and S100A9 may also play a key role in inflammation-associated cancer. [2]

Source
Recombinant human S100A8 Protein (rhS100A8), Met 1-Glu 93 (Accession # AAH05928)was expressed in E.coli cell.

Molecular Characterization
rhS100A8 contains no tag and has a calculated MW of 10.8 kDa. In DTT-reduced SDS-PAGE, rhS100A6 protein migrates as predicted.

Endotoxin
Less than 1.0 EU per μg of the rhS100A8 by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
N/A

References

(1)Schäfer BW, et al., 1996, Trends Biochem. Sci. 21 (4): 134–40.
(2)YASUHIRO ITO, et al., 2009, Anticancer Research October, 29 (10 ):4157-4161.